HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

Benzinga Newsdesk www.benzinga.com Negative 57.7%

Neg 57.7% Neu 0% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $40 to $35.